HAIXI PHARMA (02637) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend

Bulletin Express

03/10

Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes:

• Reviewing and approving the Group’s consolidated results for the financial year ended 31 December 2025, with a view to releasing the audited annual figures to the market.

• Discussing other corporate matters, notably the potential recommendation of a final dividend for the period under review.

Board composition at the time of the announcement (10 March 2026) comprises four executive directors—Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi—two non-executive directors—Mr. Xu Dong and Mr. Wang Xinkun—and three independent non-executive directors—Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.

The company will release its FY 2025 financial statements to the public following board approval on the specified date.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1148839371"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148839371\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148839371?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 16:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148839371","market":"us","top_or_hot":-1,"title":"HAIXI PHARMA (02637) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend","media":"Bulletin Express","content":"<p>Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes:</p>\n<p>• Reviewing and approving the Group’s consolidated results for the financial year ended 31 December 2025, with a view to releasing the audited annual figures to the market.</p>\n<p>• Discussing other corporate matters, notably the potential recommendation of a final dividend for the period under review.</p>\n<p>Board composition at the time of the announcement (10 March 2026) comprises four executive directors—Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi—two non-executive directors—Mr. Xu Dong and Mr. Wang Xinkun—and three independent non-executive directors—Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.</p>\n<p>The company will release its FY 2025 financial statements to the public following board approval on the specified date.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HAIXI PHARMA (02637) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHAIXI PHARMA (02637) Sets 30 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-03-10 16:44</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes:</p>\n<p>• Reviewing and approving the Group’s consolidated results for the financial year ended 31 December 2025, with a view to releasing the audited annual figures to the market.</p>\n<p>• Discussing other corporate matters, notably the potential recommendation of a final dividend for the period under review.</p>\n<p>Board composition at the time of the announcement (10 March 2026) comprises four executive directors—Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi—two non-executive directors—Mr. Xu Dong and Mr. Wang Xinkun—and three independent non-executive directors—Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.</p>\n<p>The company will release its FY 2025 financial statements to the public following board approval on the specified date.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新藥","start_time":0,"source_url":"","article_id":"1148839371","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148839371","pubTimestamp":1773132298,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes: • Reviewing and approving the Group’s consolidated results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"海西药业(02637)定于2026年3月30日召开董事会批准2025财年业绩并考虑末期股息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA, 02637) has scheduled a board meeting for Monday, 30 March 2026. The agenda includes:\n• Reviewing and approving the Group’s consolidated results for the financial year ended 31 December 2025, with a view to releasing the audited annual figures to the market.\n• Discussing other corporate matters, notably the potential recommendation of a final dividend for the period under review.\nBoard composition at the time of the announcement (10 March 2026) comprises four executive directors—Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi—two non-executive directors—Mr. Xu Dong and Mr. Wang Xinkun—and three independent non-executive directors—Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.\nThe company will release its FY 2025 financial statements to the public following board approval on the specified date.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}